SGLT2i on transthyretin amyloid cardiomyopathy - a new drug for an under-recognized cardiomyopathy

11 May 2024 (08:00 - 20:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Mr Daniel Filipe Inacio Cazeiro

Hospital Santa Maria, Lisbon (Portugal)

7 More presentations in this session

Presentation thumbnail

Clinical practice associated with 6-month use of patiromer in patients with heart failure

Doctor I. ARAUJO (Lisbon, PT)

Abstract Slides Video

Presentation thumbnail

Remote monitoring in a virtual ward safely facilitates the rapid up-titration of prognostic medication for heart failure with reduced ejection fraction patients

Doctor A. Kirupananthavel (London, GB)

Abstract Slides Video

Presentation thumbnail

Single centre 3-year experience in intermittent levosimendan infusion

Doctor F. Gerardo (Amadora, PT)

Abstract Slides Video

Presentation thumbnail

Initial experience of vericiguat treatment in patients with heart failure and high risk of decompensation.

Doctor M. Groba Marco (Las Palmas de Gran Canaria, ES)

Abstract Slides Video

Presentation thumbnail

SGLT2 inhibitors impact on loop diuretic requirement in a community heart failure cohort

Doctor M. Killian (Waterford, IE)

Abstract Slides Video

Access the full session

Session thumbnail

ePosters in chronic heart failure - pharmacotherapy 5

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024

You may be interested in

Congress Presentation

SGLT2 inhibitors in wild-type transthyretin amyloid cardiomyopathy: what to expect?

Congress Presentation

Combination therapy with sglt2-inhibitors and tafamidis in transthyretin cardiomyopathy

Congress Presentation

Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources